Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z2FD
|
|||
| Former ID |
DCL001166
|
|||
| Drug Name |
BMS-908662
|
|||
| Synonyms |
BMS-908662; XL281; BMS 908662; BMS-908662 free base; 870603-16-0; GTPL7968; SCHEMBL10049428; SCHEMBL20299316; CHEMBL3545027; EXEL-2819; Carbamic acid, (5-(2-(5-chloro-2-methylphenyl)-2,3-dihydro-1-hydro; BMS908662; XL-281; XL 281; DB12854; Carbamic acid, N-(6-(2-(5-chloro-2-methylphenyl)-2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)-1H-benzimidazol-2-yl)-, methyl ester; Methyl (5-(2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)-1H-benzimidazol-2-yl)carbamate, (+/-)-; Methyl (5-(2-(5-chloro-2-methyl
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1], [2] | |
| Company |
Exelixis; Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C24H19ClN4O4
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)Cl)N2C(=O)C3=CC=CC=C3C2(C4=CC5=C(C=C4)N=C(N5)NC(=O)OC)O
|
|||
| InChI |
1S/C24H19ClN4O4/c1-13-7-9-15(25)12-20(13)29-21(30)16-5-3-4-6-17(16)24(29,32)14-8-10-18-19(11-14)27-22(26-18)28-23(31)33-2/h3-12,32H,1-2H3,(H2,26,27,28,31)
|
|||
| InChIKey |
MMNNTJYFHUDSKL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 870603-16-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7968). | |||
| REF 2 | Clinical pipeline report, company report or official report of Exelixis (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.